Get the Stockscreener App
35.98
1.56%
-0.60
Anaptysbio Inc stock is traded at $35.98, with a volume of 141.22K.
It is down -1.56% in the last 24 hours and up +16.39% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$36.58
Open:
$36.21
24h Volume:
141.22K
Relative Volume:
0.28
Market Cap:
$1.01B
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-5.9178
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
-0.47%
1M Performance:
+16.39%
6M Performance:
+69.94%
1Y Performance:
+66.10%
1-Day Range:
$35.53
$37.12
1-Week Range:
$35.53
$38.38
52-Week Range:
$12.21
$38.38
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
35.98 | 1.02B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.62 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.93 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.49 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.13 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
Using fundamentals and technicals on AnaptysBio Inc.2025 Short Interest & Reliable Price Action Trade Plans - newser.com
Can AnaptysBio Inc. stock beat market expectations this quarterWeekly Profit Analysis & Fast Entry and Exit Trade Plans - newser.com
How AnaptysBio Inc. stock reacts to job market data2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Is AnaptysBio Inc. stock positioned well for digital economyPortfolio Update Summary & AI Forecasted Stock Moves - newser.com
Why AnaptysBio Inc. stock is recommended by analystsEarnings Summary Report & Expert Curated Trade Setup Alerts - newser.com
Is AnaptysBio Inc. stock attractive for growth ETFsWeekly Risk Summary & Safe Entry Momentum Stock Tips - newser.com
Is AnaptysBio Inc. (AN6) stock worth holding before Fed meetingQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
Will AnaptysBio Inc. stock deliver shareholder valueWeekly Profit Recap & Weekly Watchlist of Top Performers - newser.com
How rising interest rates impact AnaptysBio Inc. stock2025 Pullback Review & AI Driven Price Forecasts - newser.com
AnaptysBio FY2026 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
Risk adjusted return profile for AnaptysBio Inc. analyzedQuarterly Performance Summary & Verified Stock Trade Ideas - newser.com
Is AnaptysBio Inc. (AN6) stock good for long term investingJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - newser.com
How currency fluctuations impact AnaptysBio Inc. stock2025 Year in Review & Stock Portfolio Risk Control - newser.com
Does AnaptysBio Inc. show high probability of reboundJuly 2025 Fed Impact & Weekly High Return Stock Forecasts - newser.com
Can AnaptysBio Inc. stock weather global recession2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Real time alert setup for AnaptysBio Inc. performanceVolume Spike & Reliable Entry Point Alerts - newser.com
What drives AnaptysBio Inc AN6 stock pricePrice Support Zones & Free Unlock Stock Analysis - earlytimes.in
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio FY2025 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades - Yahoo Finance
Moody Aldrich Partners LLC Sells 23,130 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Applying big data sentiment scoring on AnaptysBio Inc.Market Activity Recap & Weekly Sector Rotation Insights - newser.com
Published on: 2025-10-31 05:16:43 - newser.com
Why AnaptysBio Inc. (AN6) stock could be top winnerTrade Performance Summary & Detailed Earnings Play Alerts - newser.com
Will AnaptysBio Inc. (AN6) stock outperform benchmarksNew Guidance & Verified Trade Idea Suggestions - newser.com
Can AnaptysBio Inc. stock sustain revenue growthTrade Volume Summary & Low Volatility Stock Suggestions - newser.com
Identifying reversal signals in AnaptysBio Inc.Swing Trade & Weekly Hot Stock Watchlists - newser.com
How AnaptysBio Inc. stock benefits from tech adoption2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Published on: 2025-10-31 00:12:04 - newser.com
Will AnaptysBio Inc. stock benefit from sector rotation2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
What analysts say about AnaptysBio Inc stockInsider Trading Compliance & Small Budget Trading Portfolio - earlytimes.in
AnaptysBio, Inc. Hits New 52-Week High at $38.38 - Markets Mojo
AnaptysBio (ANAB): Assessing Valuation After Robust Phase 2b Rosnilimab Rheumatoid Arthritis Trial Results - Sahm
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
29.00 |
8,240 |
238,960 |
9,088 |
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):